
    
      This is a prospective, single center, Phase 2, double-blinded, randomized, controlled,
      parallel group trial study. Up to fifty-four (54) participants will be enrolled (based on
      power analysis based on outcomes from a previous dose-tolerance study. Screening data will be
      reviewed to determine participant eligibility. Participants who meet all inclusion criteria
      and none of the exclusion criteria will be entered into the study and randomized in to the
      Investigational Medicinal Product (IMP) or Non Investigational Medicinal Product (NIMP) at a
      2:1 ratio (NOSi:Budesonide). Each participant will be managed as an outpatient for the 42
      days of the study. Participants will be administered NOSi or budesonide in saline by
      self-administration, at home, as a sinus irrigation to their nasopharynx and sinuses once a
      day. Participants will be asked to return to the clinic for evaluations on Day 21(±2), Day
      43(±2) and Day 63 (±2) following the start of study interventions.
    
  